Extended Data Fig. 7: Restoring NF-κB activation in CARMA1-deficient Treg cells.
From: Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
a, Survival of Fcre × C1+/+ (or C1f/f) × ROSA26-stopf/f-IKK2ca mice that express one allele of IKK2ca after expression of Foxp3cre. b–d, Frequency of CD4+ and CD8+ Tconv cells with a CD44highCD62L– effector memory phenotype in LNs (b), frequency of Treg among CD4+ T cells and of eTreg cells among total Treg cells in LNs (c), and effector cytokine expression of Tconv cells after 8-h ex vivo stimulation on anti-CD3/CD28-coated plates (d) in indicated mice. e, f, Expression of indicated phospho-proteins by YFP+ Treg cells from Fcre/+ × C1+/+ or × C1f/f mice at baseline and after 30 min. Anti-CD3/CD28 in vitro stimulation. Grey solid histograms show unstained control cells. Tconv cells were used as internal controls, and showed no differences (not shown). *P < 0.05, ***P < 0.001, ****P < 0.0001 (log-rank (Mantel–Cox) test in a; one-way ANOVA with Tukey post hoc test in b–d, f).
